BF Biosciences introduces Sibionics CGM devices in Pakistan

August 20, 2026 (MLN): BF Biosciences Limited (PSX: BFBIO) has introduced Continuous Glucose Monitoring (CGM) devices in Pakistan in collaboration with SIBIONICS, China, a medical technology company specializing in continuous glucose monitoring and digital health solutions.

The devices are being introduced in Pakistan under the brand name Sibionics CGM. Founded in 2015, SIBIONICS has developed a global presence in CGM technology, with its products and services available in more than 100 countries and serving over 4 million users globally.

CGM is an emerging technology for diabetes management that enables continuous monitoring of glucose levels and trends.

It provides patients and healthcare professionals with insights into glucose patterns and the impact of food, physical activity and other lifestyle factors, supporting more informed diabetes and lifestyle management.

The launch aligns with BF Biosciences’ strategy of developing a more integrated approach to metabolic care. Sibionics CGM is intended to complement the Company’s existing metabolic portfolio, including Ferulin® (Insulin), Sematide (Semaglutide) and Zeptide® (Tirzepatide), where clinically appropriate and under the guidance of healthcare professionals.

Through the integration of medicines, devices and disease-awareness initiatives such as SlimPossible, BF Biosciences aims to support a more comprehensive approach to the management of diabetes, obesity and related metabolic conditions.

The Company will continue to keep its shareholders and the Pakistan Stock Exchange informed of material developments in accordance with applicable laws and regulations.

The aforementioned information was disseminated through a notification to Exchange.

Copyright Mettis Link News